Trial Profile

A Phase 1b, Randomized, Double-Blinded, Dose Escalation, Single Center, Repeat-Dose Safety and Pharmacodynamics Study of Orally Administered Dapansutrile Capsules in Subjects With NYHA II-III Systolic Heart Failure

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Feb 2022 According to Olatec Therapeutics Media, results form this study published in the The Journal of the American College of Cardiology (JACC).
11 Feb 2021 According to Olatec Therapeutics Media, results published in the Journal of Cardiovascular Pharmacology, the study met its primary objectives showing dapansutrile is safe and well tolerated in patients in all dose groups.
11 Feb 2021 Results published in an Olatec Therapeutics Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com